Evidence map›Paper›PMID 30318866›Full record

ArticleCancer medicine2018

Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway.

Ye Zhang, Xiaofeng Xue, Xiaoqian Zhao, Lei Qin, Yu Shen, Huiqiang Dou, Jialin Sun, Tong Wang, Da-Qing Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ye ZhangWuxi People's Hospital, Nanjing Medical University, Wuxi, China.
Xiaofeng XueFirst Affiliated Hospital of Suzhou University, Suzhou University, Suzhou, China.
Xiaoqian ZhaoCollege of Clinical Medicine, Nanjing Medical University, Nanjing, China.
Lei QinFirst Affiliated Hospital of Suzhou University, Suzhou University, Suzhou, China.
Yu ShenFirst Affiliated Hospital of Suzhou University, Suzhou University, Suzhou, China.
Huiqiang DouWuxi People's Hospital, Nanjing Medical University, Wuxi, China.
Jialin SunCollege of Clinical Medicine, Nanjing Medical University, Nanjing, China.
Tong WangWuxi People's Hospital, Nanjing Medical University, Wuxi, China.
Da-Qing YangThe Hormel Institute, University of Minnesota, Austin, Minnesota.ORCID 0000-0003-3858-1253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on previous findings, we hypothesized that Vasohibin 2 (VASH2) protein may induce epithelial-mesenchymal transition (EMT) of pancreatic cancer (PC) cells by promoting the malignant behaviors of these cells. The present study aimed to test this hypothesis and explore the possible mechanisms involved.

methodsThe expression of VASH2 in PC tissues and cell lines was detected by quantitative real-time PCR and Western blot. PC cells with overexpression or knockdown of VASH2 were used to examine the involvement of VASH2 in EMT by detecting the expression of epithelial (E-cadherin) and mesenchymal (vimentin) markers and EMT-related transcription factor ZEB1/2, in gemcitabine resistance and tumor cell invasion by apoptosis and invasion assays, and in cancer stem cell-like phenotypes by detecting the proportion of CD24

resultsWe found that VASH2 was highly expressed in PC tissues and cells. It promoted the EMT of PC cells by altering ZEB1/2 expression. VASH2 also stimulated invasion and chemotherapeutic resistance of PC cells and increased the proportion of cancer stem-like cells in PC cells. VASH2 did so by upregulating the expression of multiple molecules in the Hedgehog signaling pathway of PC cells.

conclusionVASH2 promotes malignant behaviors of PC cells by inducing EMT via activation of the Hedgehog signaling pathway.

Indexed as

Signal TransductionAngiogenic ProteinsCarcinoma, Pancreatic DuctalCell Line, TumorDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGene Knockdown TechniquesHedgehog ProteinsHumansPancreatic NeoplasmsUp-RegulationZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2Angiogenic ProteinsHedgehog ProteinsVASH2 protein, humanZEB1 protein, humanZEB2 protein, humanZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2epithelial-mesenchymal transitionHedgehog signalingpancreatic cancerVASH2ZEB1/2

Identifiers

PMID30318866
PMCPMC6246956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.